BRCA1 and ovarian serous carcinoma: The profiles of epithelial carcinomas, including ovarian serous carcinomas and CCCs, and NETs, which are rare, were compared for chemoresistance, BRCA1/2 mutations, and HRD, which affect the efficacy of PARP inhibitors.